Neomera BioLab
藥物研發平台
表现
RD 熱度指數
RD 增長指數
比較
關於Neomera BioLab
Neomera BioLab is a biotechnology company building a discovery platform for non-opioid chronic pain drugs, running wet-lab experiments and machine-learning models in one workflow for a field short of non-addictive analgesics. The obstacle it targets is that membrane-protein targets are hard to express stably, which makes highly selective candidates difficult to find through conventional screening.
Its lipid-vesicle expression system stabilises complex membrane proteins such as GPCRs and ion channels so previously undruggable targets can be screened, and binding data generated in-house then trains selectivity models that iterate candidate peptides, with initial programmes on state-independent sodium channel NaV1.8 and NaV1.9 inhibitors. The company is part of the Creative Destruction Lab advanced therapies cohort, which gives its experimental design and commercial path external review.